News & Perspective

Sep 27, 2019

Sep 27, 2019

ASP Scan (Weekly) for Sep 27, 2019

Molecular test for blood infections
Rapid TB test assessment
CRE risk in Europe
Cefto-tazo for nosocomial pneumonia
XDR typhoid in Taiwan
UK antimicrobial resistance funds
CARB-X diagnostic graduate
Outpatient antibiotic prescribing
Hospital Candida auris outbreak
AMR Challenge commitments
UK prescribing letter

Sep 23, 2019

Sep 23, 2019

Stewardship / Resistance Scan for Sep 23, 2019

AMR Challenge commitments
UK prescribing letter

Mar 08, 2019

Mar 08, 2019

ASP Scan (Weekly) for Mar 08, 2019

Home therapy for kids' cellulitis
Antibiotics and UTI relapse
Outpatient surgery overprescribing
Resistance prevalence and sepsis
Resistant gonorrhea strain
Empiric antibiotics and UTI
Surgery-linked resistant Pseudomonas
Preventing healthcare-related infection
Resistance and sustainable development
New CARB-X funding
ESBL prediction models

Nov 16, 2018

Nov 16, 2018

ASP Scan (Weekly) for Nov 16, 2018

Improper prescribing in the ER
Hospital stewardship in China
Antibiotic use in Poland
Swiss AMR-related illness, deaths
Antibiotic use in Scotland
Drug-resistant malaria in India
Spread of resistant bacteria in hospitals
Health departments against antimicrobial resistance
Public concern over antibiotic resistance

Nov 17, 2017

Nov 17, 2017

ASP Scan (Weekly) for Nov 17, 2017

Primary care stewardship
No-touch superbug disinfection
Surgical antimicrobial prescribing
Ceftriaxone-resistant gonorrhea
E coli ST131
Single-room ICU design
ECDC CRE guidance
European research funding
Optimal MDR-TB treatment
Real-time resistance tracker
Salmonella in calves
Drug-resistant malaria controversy
US AMR progress
Antimicrobial use in Northern Ireland
Resistance in space

May 10, 2017

May 10, 2017

News Scan for May 10, 2017

MRSA bacteremia
WHO on Liberia probe
Zika vaccine trial
Senate confirms FDA head
Tularemia in Australia

Oct 27, 2014

Oct 27, 2014

CSL-Novartis deal includes US cell-based flu vaccine plant

The $275 million deal will make the company the second leading player in the $4 billion global flu vaccine market.

Dec 11, 2012

Dec 11, 2012

HHS offers some forecasts on medical countermeasures

(CIDRAP News) – A new report from the US Department of Health and Human Services (HHS) offers a few predictions on when certain new countermeasures against biological threats will become available, including a forecast for two novel influenza drugs and possibly a next-generation anthrax vaccine within the next 5 years.

Jun 08, 2012

Pages

Sort Results By:

 Sort Results By:

Narrow results by:

by country

by organization

Newsletter Sign-up

Get CIDRAP news and other free newsletters.

Sign up now»

OUR UNDERWRITERS

Unrestricted financial support provided by

Bentson Foundation Gilead 
Grant support for ASP provided by


bioMérieux

  Become an underwriter»